A Health 4.0 Based Approach Towards the Management of Multiple Sclerosis
暂无分享,去创建一个
Christoph Thuemmler | Christos Politis | Nikolaos Grigoriadis | Ai Keow Lim | Christos Bakirtzis | Kostas Danas | C. Politis | N. Grigoriadis | K. Danas | Christoph Thuemmler | C. Bakirtzis
[1] Robert W Motl,et al. Internet intervention for increasing physical activity in persons with multiple sclerosis , 2011, Multiple sclerosis.
[2] Helga E de Vries,et al. Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration? , 2010, Mitochondrion.
[3] Wayne H. Wolf,et al. Cyber-physical Systems , 2009, Computer.
[4] P Michael Ho,et al. Medication Adherence: Its Importance in Cardiovascular Outcomes , 2009, Circulation.
[5] Christine Stadelmann,et al. Wallerian Degeneration: A Major Component of Early Axonal Pathology in Multiple Sclerosis , 2010, Brain pathology.
[6] Jennifer Smrtka,et al. Loss of mobility and the patient burden of multiple sclerosis: expert opinion on relevance to daily clinical practice , 2016, Postgraduate medicine.
[7] E. Deci,et al. Facilitating health behaviour change and its maintenance: Interventions based on Self-Determination Theory , 2008 .
[8] E. Deci,et al. Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being. , 2000, The American psychologist.
[9] Mondher Toumi,et al. The payer’s perspective: What is the burden of MS and how should the patient’s perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment? , 2016, Multiple sclerosis.
[10] Michelle H Cameron,et al. Measurement and treatment of imbalance and fall risk in multiple sclerosis using the international classification of functioning, disability and health model. , 2013, Physical medicine and rehabilitation clinics of North America.
[11] J M Land,et al. Nitric Oxide‐Mediated Mitochondrial Damage in the Brain: Mechanisms and Implications for Neurodegenerative Diseases , 1997, Journal of neurochemistry.
[12] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[13] M. Filippo,et al. Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes , 2009, Journal of Neurology, Neurosurgery & Psychiatry.
[14] P Lindgren,et al. Costs and quality of life of patients with multiple sclerosis in Europe , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[15] Thomas Nyffeler,et al. Cognitive Impairment in Multiple Sclerosis: Clinical Manifestation, Neuroimaging Correlates, and Treatment , 2016, Seminars in Neurology.
[16] David H. Miller,et al. Gray matter atrophy is related to long‐term disability in multiple sclerosis , 2008, Annals of neurology.
[17] L. Osterberg,et al. Adherence to medication. , 2005, The New England journal of medicine.
[18] L. Vécsei,et al. The epidemiology of multiple sclerosis in Europe , 2006, European journal of neurology.
[19] Hans Lassmann,et al. Mitochondrial defects in acute multiple sclerosis lesions , 2008, Brain : a journal of neurology.
[20] A. Thompson,et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. , 2008, Brain : a journal of neurology.
[21] Anthony Feinstein,et al. Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study , 2016, BMC Research Notes.
[22] Ioannis Milonas,et al. Axonal damage in multiple sclerosis: a complex issue in a complex disease , 2004, Clinical Neurology and Neurosurgery.
[23] Howard L Zwibel,et al. Improving quality of life in multiple sclerosis: an unmet need. , 2011, The American journal of managed care.
[24] O Ciccarelli,et al. The role of mitochondria in axonal degeneration and tissue repair in MS , 2012, Multiple sclerosis.
[25] A. Thompson,et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis , 2005, The Lancet Neurology.
[26] F. Collins,et al. A new initiative on precision medicine. , 2015, The New England journal of medicine.
[27] Aj Thompson,et al. MSIF Atlas of MS database update: multiple sclerosis resources in the world 2013 , 2012 .
[28] Kathleen Costello,et al. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. , 2008, Medscape journal of medicine.
[29] B. Trapp,et al. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis , 2011, Progress in Neurobiology.
[30] M.A.J. Visschedijk. Evaluation of a psychosocial intervention program for patients with multiple sclerosis , 1999 .
[31] S. Reingold,et al. Defining the clinical course of multiple sclerosis , 1996, Neurology.
[32] Neeta Garg,et al. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis , 2015, Brain and behavior.
[33] David E Jones. Early Relapsing Multiple Sclerosis , 2016, Continuum.
[34] Bruce H Dobkin,et al. The Promise of mHealth , 2011, Neurorehabilitation and neural repair.
[35] Anastasius Gavras,et al. Requirements Engineering for Digital Health , 2014 .
[36] Patrick Vermersch,et al. The patient's perspective: How to create awareness for improving access to care and treatment of MS patients? , 2016, Multiple sclerosis.
[37] Marjorie Skubic,et al. Exploring the feasibility and acceptability of sensor monitoring of gait and falls in the homes of persons with multiple sclerosis. , 2016, Gait & posture.
[38] Gavin Giovannoni,et al. The importance of a multi-disciplinary perspective and patient activation programmes in MS management , 2016, Multiple sclerosis.
[39] Peter K Stys,et al. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis , 2009, The Lancet Neurology.